| Nov 12 |
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia
|
| Nov 8 |
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
|
| Nov 5 |
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know
|
| Oct 29 |
BioXcel Therapeutics to Present at ThinkEquity Conference
|
| Oct 15 |
BioXcel announces defense grant to UNC to fund study for treating acute stress disorder
|
| Oct 15 |
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder
|
| Sep 19 |
BioXcel ends commercial support for Igalmi as focus turns to neuro candidate
|
| Sep 19 |
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
|
| Sep 5 |
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
|
| Aug 30 |
BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
|
